Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Trade-offs in cervical cancer prevention: balancing benefits and risks.

Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ.

Arch Intern Med. 2008 Sep 22;168(17):1881-9. doi: 10.1001/archinte.168.17.1881.

2.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

3.

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ.

J Natl Cancer Inst. 2008 Mar 5;100(5):308-20. doi: 10.1093/jnci/djn019. Epub 2008 Feb 26.

4.

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group.

J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.

5.

Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL.

Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, Woodward L.

J Fam Pract. 1998 Feb;46(2):136-41.

PMID:
9487319
6.
7.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

8.

Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].

Kulasingam SL, Havrilesky L, Ghebre R, Myers ER.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May.

9.

Screening for cervical cancer: new alternatives and research.

Lörincz AT.

Salud Publica Mex. 2003;45 Suppl 3:S376-87. Review.

PMID:
14746031
10.

Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities?

Fait G, Daniel Y, Kupferminc MJ, Lessing JB, Niv J, Bar-Am A.

Gynecol Oncol. 1998 Sep;70(3):319-22.

PMID:
9790781
11.

Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy?

Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, Borgatta L, Buck H, Kramer L, Rubin R.

J Fam Pract. 1998 Feb;46(2):125-34.

PMID:
9487318
12.

HPV testing is an efficient management choice for women with inadequate liquid-based cytology in cervical cancer screening.

Giorgi Rossi P, Carozzi F, Collina G, Confortini M, Dalla Palma P, De Lillo M, Del Mistro A, Ghiringhello B, Gillio-Tos A, Maioli P, Pellegrini A, Schiboni ML, Segnan N, Zaffina LM, Zorzi M, Ronco G; NTCC Working Group.

Am J Clin Pathol. 2012 Jul;138(1):65-71. doi: 10.1309/AJCP6J2OEFOYTRFD.

13.
14.

Chapter 14: Role of triage testing in cervical cancer screening.

Solomon D.

J Natl Cancer Inst Monogr. 2003;(31):97-101. Review.

PMID:
12807952
16.
17.
19.
20.

Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS).

Sherman ME, Schiffman M, Cox JT; Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group.

J Natl Cancer Inst. 2002 Jan 16;94(2):102-7.

Items per page

Supplemental Content

Write to the Help Desk